Neurocrine Biosciences (NBIX) Competitors $128.04 -1.37 (-1.05%) Closing price 07/3/2025 03:51 PM EasternExtended Trading$127.38 -0.65 (-0.51%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NBIX vs. ALNY, BIIB, INCY, UTHR, EXEL, BMRN, EXAS, RGEN, MDGL, and HALOShould you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), and Halozyme Therapeutics (HALO). These companies are all part of the "biotechnology" industry. Neurocrine Biosciences vs. Its Competitors Alnylam Pharmaceuticals Biogen Incyte United Therapeutics Exelixis BioMarin Pharmaceutical Exact Sciences Repligen Madrigal Pharmaceuticals Halozyme Therapeutics Alnylam Pharmaceuticals (NASDAQ:ALNY) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk. Do insiders and institutionals have more ownership in ALNY or NBIX? 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 4.8% of Neurocrine Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend ALNY or NBIX? Alnylam Pharmaceuticals currently has a consensus target price of $340.00, suggesting a potential upside of 2.43%. Neurocrine Biosciences has a consensus target price of $162.00, suggesting a potential upside of 26.53%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Neurocrine Biosciences is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 20 Buy rating(s) 0 Strong Buy rating(s) 2.79Neurocrine Biosciences 0 Sell rating(s) 3 Hold rating(s) 19 Buy rating(s) 0 Strong Buy rating(s) 2.86 Which has higher valuation and earnings, ALNY or NBIX? Neurocrine Biosciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.35B18.43-$278.16M-$2.09-158.82Neurocrine Biosciences$2.36B5.38$341.30M$2.9543.40 Is ALNY or NBIX more profitable? Neurocrine Biosciences has a net margin of 12.68% compared to Alnylam Pharmaceuticals' net margin of -11.49%. Neurocrine Biosciences' return on equity of 11.81% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-11.49% -510.31% -6.48% Neurocrine Biosciences 12.68%11.81%8.59% Which has more risk and volatility, ALNY or NBIX? Alnylam Pharmaceuticals has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. Does the media refer more to ALNY or NBIX? In the previous week, Alnylam Pharmaceuticals had 9 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 19 mentions for Alnylam Pharmaceuticals and 10 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 1.32 beat Alnylam Pharmaceuticals' score of 0.98 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 10 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryNeurocrine Biosciences beats Alnylam Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBIX vs. The Competition Export to ExcelMetricNeurocrine BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.78B$2.43B$5.55B$9.04BDividend YieldN/A1.67%5.22%4.00%P/E Ratio43.409.2227.6420.24Price / Sales5.38683.39418.75118.07Price / Cash38.20158.5936.8958.10Price / Book5.014.588.035.67Net Income$341.30M$31.34M$3.18B$249.21M7 Day Performance2.08%3.25%2.93%3.28%1 Month Performance2.11%3.46%1.72%3.95%1 Year Performance-7.94%0.77%34.39%20.98% Neurocrine Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBIXNeurocrine Biosciences4.9241 of 5 stars$128.04-1.1%$162.00+26.5%-7.9%$12.78B$2.36B43.401,800Positive NewsALNYAlnylam Pharmaceuticals4.2971 of 5 stars$326.09+1.0%$340.00+4.3%+32.2%$42.52B$2.35B-156.022,000Analyst UpgradeBIIBBiogen4.9302 of 5 stars$125.59-0.4%$188.48+50.1%-41.2%$18.40B$9.68B12.407,605INCYIncyte4.4294 of 5 stars$68.10-0.4%$74.53+9.4%+19.4%$13.18B$4.24B212.822,617UTHRUnited Therapeutics4.9954 of 5 stars$287.35+1.1%$386.15+34.4%-6.4%$12.96B$2.88B11.471,305EXELExelixis4.7416 of 5 stars$44.08+0.9%$43.56-1.2%+107.7%$12.02B$2.17B20.041,147Trending NewsAnalyst RevisionBMRNBioMarin Pharmaceutical4.9448 of 5 stars$54.97-0.4%$93.45+70.0%-29.7%$10.54B$2.85B20.443,040Analyst ForecastEXASExact Sciences4.9417 of 5 stars$53.14-1.0%$70.40+32.5%+18.5%$10.02B$2.83B-9.647,000Analyst RevisionRGENRepligen4.7707 of 5 stars$124.38+0.7%$172.83+39.0%+6.1%$6.99B$634.44M-276.401,778News CoverageMDGLMadrigal Pharmaceuticals4.0866 of 5 stars$302.64+0.6%$420.63+39.0%+7.9%$6.72B$317.38M-16.7790HALOHalozyme Therapeutics4.823 of 5 stars$52.02-0.4%$61.90+19.0%+4.8%$6.41B$1.02B13.84390News CoverageHigh Trading Volume Related Companies and Tools Related Companies Alnylam Pharmaceuticals Competitors Biogen Competitors Incyte Competitors United Therapeutics Competitors Exelixis Competitors BioMarin Pharmaceutical Competitors Exact Sciences Competitors Repligen Competitors Madrigal Pharmaceuticals Competitors Halozyme Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBIX) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
